Further assessment of cell viability in MIA PaCa-2 and PANC-1 cells treated with bufalin, the identified inhibitor of BCAT1, revealed IC50 values of 0.26 ± 0.046 μM and 0.32 ± 0.086 μM, respectively, indicating an effective outcome in pancreatic cancer (Fig. S5). The gene discussed is BCAT1; the disease is pancreatic neoplasm.